1,091
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Pharmacological characterization of the α2A-adrenergic receptor inhibiting rat hippocampal CA3 epileptiform activity: comparison of ligand efficacy and potency

, , , , , , , ORCID Icon, & ORCID Icon show all
Pages 580-587 | Received 03 Jun 2022, Accepted 02 Aug 2022, Published online: 19 Aug 2022

References

  • Giorgi FS, Pizzanelli C, Biagioni F, et al. The role of norepinephrine in epilepsy: from the bench to the bedside. Neurosci Biobehav Rev. 2004;28(5):507–524.
  • Happe HK, Coulter CL, Gerety ME, et al. α2-adrenergic receptor development in rat CNS: an autoradiographic study. Neuroscience. 2004;123(1):167–178.
  • Zilles K, Gross G, Schleicher A, et al. Regional and laminar distributions of alpha1-adrenoceptors and their subtypes in human and rat hippocampus. Neuroscience. 1991;40(2):307–320.
  • Weinshenker D, Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther. 2002;94(3):213–233.
  • Clinckers R, Zgavc T, Vermoesen K, et al. Pharmacological and neurochemical characterization of the involvement of hippocampal adrenoreceptor subtypes in the modulation of acute limbic seizures. J Neurochem. 2010;115(6):1595–1607.
  • Ghasemi M, Mehranfard N. Mechanisms underlying anticonvulsant and proconvulsant actions of norepinephrine. Neuropharmacology. 2018;137:297–308.
  • Iváñez V, Ojeda J. Exacerbation of seizures in medial temporal lobe epilepsy due to an alpha1-adrenergic antagonist. Epilepsia. 2006;47(10):1741–1742.
  • Löscher W, Czuczwar SJ. Comparison of drugs with different selectivity for Central alpha1- and alpha2-adrenoceptors in animal models of epilepsy. Epilepsy Res. 1987;1(3):165–172.
  • Weinshenker D, Szot P, Miller NS, et al. Alpha(1) and beta(2)-adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine. J Pharmacol Exp Ther. 2001;298(3):1042–1048.
  • Jurgens CWD, Hammad HM, Lichter JA, et al. α2A adrenergic receptor activation inhibits epiletiform activity in the rat hippocampal CA3 region. Mol Pharmacol. 2007;71(6):1572–1581.
  • Gill CH, Soffin EM, Hagan JJ, et al. 5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology. 2002;42(1):82–92.
  • Tesson F, Limon-Boulez I, Urban P, et al. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem. 1995;270(17):9856–9861.
  • Hauser WA. Seizure disorders: the changes with age. Epilepsia. 1992;33 Suppl 4(Suppl 4):S6–S14.
  • Savic I. Sex differences in human epilepsy. Exp Neurol. 2014;259:38–43.
  • Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959;14(1):48–58.
  • Uhlén S, Dambrova M, Näsman J, et al. 3H]RS79948-197 binding to human, rat, guinea pig and pig α2A-, α2B- and α2C-adrenoceptor. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol. 1998;343(1):93–101.
  • Beck SG, Choi KC, List TJ. Comparison of 5-hydroxytryptamine1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. J Pharmacol Exp Ther. 1992;263(1):350–359.
  • Ruffolo RR, Jr, Rice PJ, Patil PN, et al. Differences in the applicability of the easson-stedman hypothesis to the alpha1- and alpha2-adrenergic effects of phenethylamines and imidazolines. Eur J Pharmacol. 1983;86(3-4):471–475.
  • Jasper JR, Lesnick JD, Chang LK, et al. Ligand efficacy and potency at recombinant α2-adrenergic receptors: agonist-mediated [35S]GTPγS binding. Biochem Pharmacol. 1998;55(7):1035–1043.
  • Chen X, Xu Y, Qu L, et al. Molecular mechanism for ligand recognition and subtype selectivity of α2C-Adrenergic receptor. Cell Rep. 2019;29(10):2936–2943.e4.
  • Yuan D, Liu Z, Kaindl J, et al. Activation of the α2B-adrenoceptor by the sedative sympatholytic dexmedetomidine. Nat Chem Biol. 2020;16(5):507–512.
  • Qu L, Zhou Q, Xu Y, et al. Structural basis of the diversity of adrenergic receptors. Cell Rep. 2019;29(10):2929–2935.e4.
  • Xu J, Cao S, Hübner H, et al. Structural insights into ligand recognition, activation, and signaling of the α2Aadrenergic receptor. Sci Adv. 2022;8(9)eabj:5347.
  • Strange PG. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol. 2008;153(7):1353–1363.
  • Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–157.